Travere Therapeutics Inc (NAS:TVTX)
$ 6.16 -0.18 (-2.84%) Market Cap: 468.95 Mil Enterprise Value: 431.93 Mil PE Ratio: 0 PB Ratio: 6.33 GF Score: 54/100

Travere Therapeutics Inc at Guggenheim Healthcare Talks: Genomic Medicines and Rare Disease Days (Virtual) Transcript

Apr 04, 2023 / 07:55PM GMT
Release Date Price: $21.83 (-3.02%)
Vamil Diwan
Guggenheim Partners - Analyst

All right, I think we are live. Good afternoon, everyone. Thanks for joining us on the second day of our fifth annual Guggenheim Genomic Medicines and Rare Disease Day. I'm Vamil Divan, one of the senior analyst here at Guggenheim. Joining -- Areseniy is also on the line from the Guggenheim side. And we got the full team here from the Travere Therapeutics side for our next session.

Thanks so much to all of you for joining us. We have Eric Dube, who is the President and CEO. We have Chris Cline, the CFO; and Peter Heerma, the CCO, along with Naomi Eichenbaum from Investor Relations.

And obviously, a lot to get to. So I'm just going to jump right in. But before I do that, for those of you listening in, if you have any questions that you want me to ask, please feel free to e-mail me at [email protected] and I'll work them into the conversation. But I thought we could get started.

We obviously, this weekend, just had some additional data released at WCN. So maybe if you guys just want to share, I guess I'll turn this to

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot